LTS ist global führend bei transdermalen therapeutischen Systemen und oralen Wirkstofffilmen.

From the initial vision to a leading partner

History of LTS2017-03-01T12:50:23+00:00

It all started with the vision of a transdermal patch, and has developed into a success story that has lasted to this day: read on for an overview of the history of LTS and its major milestones.

1980
The Lohmann Company in Neuwied, West Germany, a specialist in technical adhesive tapes starts developing the idea of transdermal therapeutic systems (TTS).

1984
LTS, LOHMANN Therapie-Systeme GmbH & Co. KG is founded as a subsidiary of the Lohmann Group in Neuwied. The first TTS matrix system from LTS achieves approval and is launched, a nitroglycerin patch (Deponit®).

1986
LTS´ development, production and quality control departments move into the company’s first independent facility in Neuwied.

1988
LTS begins initial development work on oral thin films.

1991
The first nicotine patch for smoking cessation is launched in the US – developed and manufactured by LTS.

1992
LTS launches the world’s first hormone TTS matrix system (Estradiol patch).

1993
LTS Corp. is founded in in West Caldwell (USA); Completion of factory´s reconstruction work

1994
LTS moves its headquarters to Andernach.

1995
Start of Nicotine-TTS production in the USA.

1997
Listerine® Whitening Strip production starts in the USA.

1999
LTS is transformed into a non-listed public limited company. The first nicotine patch is approved in Japan.

2000
The first oral wafer product is launched and manufactured exclusively by LTS (sold as an oral hygiene product for the end customer).

2001
The first buprenorphine patch in the world is approved for treating pain relief and launched in Europe – developed and manufactured by LTS.

2002
LTS’s partner Johnson & Johnson launches the world’s first transdermal contraceptive patch (Evra®).

2004
LTS starts basic research into microneedles.

2005
Development of the first LTS-Fentanyl-TTS for the treatment chronic pain and launch by the LTS partner Nycomed. By using the LTS matrix system the content of the API can be reduced by 35% having the same efficacy.
Over 1 Billion Listerine® PocketPacks have been manufactured at LTS

2006
For the first time, a therapy is exclusively available as a transdermal system – the world’s first new chemical entity (NCE) for the treatment of Parkinson’s disease – developed and manufactured by LTS.

2007
The Exelon® patch (Rivastigmine) from Novartis, with major support from LTS, is approved and launched for the treatment of Alzheimer’s disease.

2008
The nicotine patch developed by LTS is approved and launched in Europe.

2009
Scientific symposium on TTS –„LTS-Academy“– including key opinion leaders and experts in the field.

2010
Launch of Qutenza™ (Astellas/Acorda) the first cutaneous patch with a high concentrate of capsaicin (8 %) for the local treatment of neuropathic pain.

2011
Launch of Butrans® in Japan and the USA (Hisamitsu, Purdue)
Launch of Exelon® in Japan (ONO)

2012
Launch of the Ibuprofen Patch Ibupas® by Sigma Tau; a local analgesic for the treatment of acute or chronical Tennis elbow
Launch of Neupro® in Japan (Otsuka)
LTS starts production of its first OTF for the management of breakthrough pain.

Privacy  Imprint

This website uses cookies to analyse website accesses/marketing measures. If you continue to use this website, you agree to our use of cookies. Information about cookies and your right to object.
Ok